Search

Your search keyword '"Jayson, Gordon"' showing total 662 results
Start Over Author "Jayson, Gordon"
662 results on '"Jayson, Gordon"'

1. Germline BRCA1/2 status and chemotherapy response score in high-grade serous ovarian cancer: Genetics and Genomics

Author

Morgan, Robert D., Wang, Xin, Barnes, Bethany M., Spurgeon, Laura, Carrot, Aurore, Netto, Daniel, Hasan, Jurjees, Mitchell, Claire, Salih, Zena, Desai, Sudha, Shaw, Joseph, Winter-Roach, Brett, Schlecht, Helene, Burghel, George J., Clamp, Andrew R., Edmondson, Richard J., You, Benoit, Evans, D. Gareth R., Jayson, Gordon C., and Taylor, Stephen S.

Published
2024
Full Text
View/download PDF

2. The VALTIVE1 study protocol: a study for the validation of Tie2 as the first tumour vascular response biomarker for VEGF inhibitors

Author

Carucci, Margherita, Clamp, Andrew, Zhou, Cong, Hurt, Chris, Glasspool, Rosalind, Monaghan, Phillip J., Thirkettle, Sally, Wheatley, Michael, Mahmood, Madia, Narasimham, Monica, Cox, Tracy, Morrison, Hilary, Campbell, Susan, Nelson, Annmarie, Holland-Hart, Daniella, Hopewell-Kelly, Noreen, Thomas, Abin, Porter, Catharine, Slusarczyk, Magdalena, Irving, Alys, Dive, Caroline, Adams, Richard, and Jayson, Gordon C.

Published
2024
Full Text
View/download PDF

5. Once daily cediranib and weekly paclitaxel to prevent malignant bowel obstruction in at-risk patients with platinum-resistant ovarian cancer (CEBOC): a single-arm, phase II safety trial

Author

Murphy, Alexander D, Porter, Catharine, White, Ann, Irving, Alys, Adams, Richard, Ray, Ruby, Casbard, Angela, Mahmood, Reem D, Karanth, Suman, Zhou, Cong, Pugh, Julia, Wheeler, Chelsey, Roberts, Victoria, Arnetoli, Giorgio, Salih, Zena, Hasan, Jurjees, Mitchell, Claire, Morgan, Robert D, Clamp, Andrew R, Jayson, Gordon C, and Gough, Linda

Published
2024
Full Text
View/download PDF

6. Homologous recombination deficiency in newly diagnosed FIGO stage III/IV high-grade epithelial ovarian cancer: a multi-national observational study

Author

Morgan, Robert D., Clamp, Andrew R., Barnes, Bethany M., Timms, Kirsten, Schlecht, Helene, Yarram-Smith, Laura, Wallis, Yvonne, Valganon-Petrizan, Mikel, MacMahon, Suzanne, White, Rhian, Morgan, Sian, McKenna, Sarah, Hudson, Emma, Tookman, Laura, George, Angela, Manchanda, Ranjit, Sundar, Sudha S, Nicum, Shibani, Brenton, James D., Kristeleit, Rebecca S., Banerjee, Susana, McNeish, Iain A., Ledermann, Jonathan A., Taylor, Stephen S., Evans, D Gareth R., and Jayson, Gordon C.

Published
2023
Full Text
View/download PDF

12. Objective responses to first-line neoadjuvant carboplatin–paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial

Author

Morgan, Robert D, McNeish, Iain A, Cook, Adrian D, James, Elizabeth C, Lord, Rosemary, Dark, Graham, Glasspool, Rosalind M, Krell, Jonathan, Parkinson, Christine, Poole, Christopher J, Hall, Marcia, Gallardo-Rincón, Dolores, Lockley, Michelle, Essapen, Sharadah, Summers, Jeff, Anand, Anjana, Zachariah, Abel, Williams, Sarah, Jones, Rachel, Scatchard, Kate, Walther, Axel, Kim, Jae-Weon, Sundar, Sudha, Jayson, Gordon C, Ledermann, Jonathan A, and Clamp, Andrew R

Published
2021
Full Text
View/download PDF

13. ICON 9—an international phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy

Author

Elyashiv, Osnat, Ledermann, Jonathan, Parmar, Gita, Farrelly, Laura, Counsell, Nicholas, Feeney, Amanda, El-Khouly, Fatima, Macdonald, Ian, Neto, Andreia, Arthur-Darkwa, Esther, Burnett, Eva, Jayson, Gordon C, Mileshkin, Linda, Gourley, Charlie, and Nicum, Shibani

Published
2021
Full Text
View/download PDF

16. An Advanced Clinical Practitioner And Specialist Clinical Pharmacist-Led Outpatient Service To Deliver Maintenance Poly (ADP-Ribose) Polymerase Inhibitors Therapies To Treat Women With Advanced-Stage Or Relapsed, Platinum-Sensitive High-Grade Epithelial Ovarian Cancer

Author

Donaldson, Clare, Sterigou, Polyxeni, Collins, Joanne, Penn, Samantha, Moohan, Emma, Morgan, Robert D., Salih, Zena, Mitchell, Claire, Clamp, Andrew R., Jayson, Gordon C., and Hasan, Jurjees

Published
2025
Full Text
View/download PDF

18. Mainstreaming germline BRCA1/2 testing in non-mucinous epithelial ovarian cancer in the North West of England

Author

Flaum, Nicola, Morgan, Robert D., Burghel, George J., Bulman, Michael, Clamp, Andrew R., Hasan, Jurjees, Mitchell, Claire L., Badea, Doina, Moon, Sarah, Hogg, Martin, Hadjiyiannakis, Dennis, Clancy, Tara, Schlecht, Helene, Woodward, Emma R., Crosbie, Emma J., Edmondson, Richard J., Wallace, Andrew J., Jayson, Gordon C., Lalloo, Fiona I., Harkness, Elaine F., and Evans, D. Gareth R.

Published
2020
Full Text
View/download PDF

20. Effect of oxaliplatin plus 5-fluorouracil or capecitabine on circulating and imaging biomarkers in patients with metastatic colorectal cancer: a prospective biomarker study

Author

Mahmood, Reem D., Shaw, Danielle, Descamps, Tine, Zhou, Cong, Morgan, Robert D., Mullamitha, Saifee, Saunders, Mark, Mescallado, Nerissa, Backen, Alison, Morris, Karen, Little, Ross A., Cheung, Susan, Watson, Yvonne, O’Connor, James P. B., Jackson, Alan, Parker, Geoff J. M., Dive, Caroline, and Jayson, Gordon C.

Published
2021
Full Text
View/download PDF

23. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials

Author

Tropé G., Claes, Dobbs, Stephen, Essapen, Sharadah, Hoskins, P., Green, John, Gilby, E., Van Baal, M., Twigg, Jeremy, Van Der Burg, Maria E.L., Godfrey, Keith, Lacave, Angel J., Angioli, R., Nath, Rahul, Chin, Kirk, Redman, Charles, Lotocki, R., Olaitan, Adeola, Mosgaard, B., Rustin, G., Ind, Thomas, Persic, Mojca, Hogg, Martin, Van Der Velden, J., Ledermann, J., Peter Sykes, Peter Sykes, Madhavan, Krishnawam, Kannisto, P., Hird, Vicky, Evans, A., Sandvei R., R., Gauthier, P., Cruickshank, D.J., Ottevanger, P.B., Pearson, Sheila, Kitchener, Henry, Hall, Marcia, Bessette, P., Pecorelli, S., Gerdin, E., Lopes, Tito, Fish, Andrew, Barlow., Clare, Van Eygen, K., Floquet, A., Tholander, B., Gul, N., Gornall, Robert, Luesley, David, Kirwan, Philip, Symonds, Paul, Henry, Richard, Poole, David, McNeish, Ian, Hocking, Mark, Sammaraie, Al, Speiser, P., Leblanc, E., Green, J.A., De Oliveira, C.F., Grimshaw, R., Zola, P., Parkin, David, Lamb, Martin, Hong, Anne, Gillespie, Alan, Hamid, Abdel, Ahmed, Ahmed, Plante, M., De Valk, B., Nordin, A., Clamp, Andrew, Perez, David, Graham Dark, Graham Dark, Ferguson, Michelle, MacGregor, Carol, Skailes, Geraldine, Jones, Rachel, Cawdell, G., Leeson, Simon, Elit, L., Dittrich, C., Gotlieb, W., Cullimore, John, Crosse, Barbara, Ridley, Paul, Head, Anthony, Nieto, Joaquin, Awwad, Saif, Brinkmann, Dirk, Eustace, Damian, Hindley, Andrew, Katsaros, D., Popadiuk, C., Kristeller, Tome, Redman, C., Chan, S., Marth, C., Yiannakis, Dennis, Lankaster, Kate, Beynon, Gareth, Suhail, Anwar, Indrajit, Fernando, Quigley, Mary, Adeyemi, Olu, Lofts, Fiona, McNally, Orla, Tristam, Amanda, Lee, Martin, Counsell, R., Gleeson, N., Papadopoulos, A., Maggino, T., Honkoop, A., Ghatage, P., Vermorken, J.B., De Greve, J., Boman, K., Petru, E, Amant, F., Vergote, Ignace, Coens, Corneel, Nankivell, Matthew, Kristensen, Gunnar B, Parmar, Mahesh K B, Ehlen, Tom, Jayson, Gordon C, Johnson, Nick, Swart, Ann Marie, Verheijen, René, McCluggage, W Glenn, Perren, Tim, Panici, Pierluigi Benedetti, Kenter, Gemma, Casado, Antonio, Mendiola, Cesar, Stuart, Gavin, Reed, Nick S, and Kehoe, Sean

Published
2018
Full Text
View/download PDF

28. #512 Real-World utilisation and clinical outcomes of patients with BRCA-mutated advanced ovarian cancer treated with olaparib in the first-line maintenance setting: 2-year clinical outcomes of the pan-European OVAL-1 study

Author

Lorusso, Domenica, primary, Garbay, Delphine, additional, Roger Asselain, Bernard Jean, additional, Miller, Rowan, additional, Raspagliesi, Francesco, additional, Zamagni, Claudio, additional, Leary, Alexandra, additional, Bellier, Charlotte, additional, Glasspool, Ros, additional, Jayson, Gordon, additional, Grevat, Emmanuelle, additional, Kertous, Mehdi, additional, Sabatucci, Ilaria, additional, Padrone, Claudia, additional, Jayia, Parveen, additional, Hada, Manila, additional, Mclaurin, Kimmie, additional, and Gourley, Charlie, additional

Published
2023
Full Text
View/download PDF

29. Supplementary Table S2. from Multi-Maintenance Olaparib Therapy in Relapsed, Germline BRCA1/2-Mutant High-Grade Serous Ovarian Cancer (MOLTO): A Phase II Trial

Author

Morgan, Robert D., primary, Clamp, Andrew R., primary, White, Daniel J., primary, Price, Marcus, primary, Burghel, George J., primary, Ryder, W. David J., primary, Mahmood, Reem D., primary, Murphy, Alexander D., primary, Hasan, Jurjees, primary, Mitchell, Claire L., primary, Salih, Zena, primary, Wheeler, Chelsey, primary, Buckley, Emma, primary, Truelove, Joanna, primary, King, Georgia, primary, Ainaoui, Yasmina, primary, Bhaskar, Sanjeev S., primary, Shaw, Joseph, primary, Evans, D. Gareth R., primary, Kilerci, Bedirhan, primary, Pearce, Simon P., primary, Brady, Gerard, primary, Dive, Caroline, primary, O'Connor, James P.B., primary, Wallace, Andrew J., primary, Rothwell, Dominic G., primary, Edmondson, Richard J., primary, and Jayson, Gordon C., primary

Published
2023
Full Text
View/download PDF

30. Supplementary Methodology 1 from Multi-Maintenance Olaparib Therapy in Relapsed, Germline BRCA1/2-Mutant High-Grade Serous Ovarian Cancer (MOLTO): A Phase II Trial

Author

Morgan, Robert D., primary, Clamp, Andrew R., primary, White, Daniel J., primary, Price, Marcus, primary, Burghel, George J., primary, Ryder, W. David J., primary, Mahmood, Reem D., primary, Murphy, Alexander D., primary, Hasan, Jurjees, primary, Mitchell, Claire L., primary, Salih, Zena, primary, Wheeler, Chelsey, primary, Buckley, Emma, primary, Truelove, Joanna, primary, King, Georgia, primary, Ainaoui, Yasmina, primary, Bhaskar, Sanjeev S., primary, Shaw, Joseph, primary, Evans, D. Gareth R., primary, Kilerci, Bedirhan, primary, Pearce, Simon P., primary, Brady, Gerard, primary, Dive, Caroline, primary, O'Connor, James P.B., primary, Wallace, Andrew J., primary, Rothwell, Dominic G., primary, Edmondson, Richard J., primary, and Jayson, Gordon C., primary

Published
2023
Full Text
View/download PDF

31. Supplementary Figure S3. from Multi-Maintenance Olaparib Therapy in Relapsed, Germline BRCA1/2-Mutant High-Grade Serous Ovarian Cancer (MOLTO): A Phase II Trial

Author

Morgan, Robert D., primary, Clamp, Andrew R., primary, White, Daniel J., primary, Price, Marcus, primary, Burghel, George J., primary, Ryder, W. David J., primary, Mahmood, Reem D., primary, Murphy, Alexander D., primary, Hasan, Jurjees, primary, Mitchell, Claire L., primary, Salih, Zena, primary, Wheeler, Chelsey, primary, Buckley, Emma, primary, Truelove, Joanna, primary, King, Georgia, primary, Ainaoui, Yasmina, primary, Bhaskar, Sanjeev S., primary, Shaw, Joseph, primary, Evans, D. Gareth R., primary, Kilerci, Bedirhan, primary, Pearce, Simon P., primary, Brady, Gerard, primary, Dive, Caroline, primary, O'Connor, James P.B., primary, Wallace, Andrew J., primary, Rothwell, Dominic G., primary, Edmondson, Richard J., primary, and Jayson, Gordon C., primary

Published
2023
Full Text
View/download PDF

32. Data from Multi-Maintenance Olaparib Therapy in Relapsed, Germline BRCA1/2-Mutant High-Grade Serous Ovarian Cancer (MOLTO): A Phase II Trial

Author

Morgan, Robert D., primary, Clamp, Andrew R., primary, White, Daniel J., primary, Price, Marcus, primary, Burghel, George J., primary, Ryder, W. David J., primary, Mahmood, Reem D., primary, Murphy, Alexander D., primary, Hasan, Jurjees, primary, Mitchell, Claire L., primary, Salih, Zena, primary, Wheeler, Chelsey, primary, Buckley, Emma, primary, Truelove, Joanna, primary, King, Georgia, primary, Ainaoui, Yasmina, primary, Bhaskar, Sanjeev S., primary, Shaw, Joseph, primary, Evans, D. Gareth R., primary, Kilerci, Bedirhan, primary, Pearce, Simon P., primary, Brady, Gerard, primary, Dive, Caroline, primary, O'Connor, James P.B., primary, Wallace, Andrew J., primary, Rothwell, Dominic G., primary, Edmondson, Richard J., primary, and Jayson, Gordon C., primary

Published
2023
Full Text
View/download PDF

34. Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial

Author

Ledermann, Jonathan A, Embleton, Andrew C, Raja, Fharat, Perren, Timothy J, Jayson, Gordon C, Rustin, Gordon J S, Kaye, Stan B, Hirte, Hal, Eisenhauer, Elizabeth, Vaughan, Michelle, Friedlander, Michael, González-Martín, Antonio, Stark, Daniel, Clark, Elizabeth, Farrelly, Laura, Swart, Ann Marie, Cook, Adrian, Kaplan, Richard S, and Parmar, Mahesh K B

Published
2016
Full Text
View/download PDF

36. A living biobank of ovarian cancer ex vivo models reveals profound mitotic heterogeneity

Author

Nelson, Louisa, Tighe, Anthony, Golder, Anya, Littler, Samantha, Bakker, Bjorn, Moralli, Daniela, Murtuza Baker, Syed, Donaldson, Ian J., Spierings, Diana C. J., Wardenaar, René, Neale, Bethanie, Burghel, George J., Winter-Roach, Brett, Edmondson, Richard, Clamp, Andrew R., Jayson, Gordon C., Desai, Sudha, Green, Catherine M., Hayes, Andy, Foijer, Floris, Morgan, Robert D., and Taylor, Stephen S.

Published
2020
Full Text
View/download PDF

39. Real-World Concordance between Germline and Tumour BRCA1/2 Status in Epithelial Ovarian Cancer.

Author

Morgan, Robert D., Burghel, George J., Schlecht, Helene, Clamp, Andrew R., Hasan, Jurjees, Mitchell, Claire L., Salih, Zena, Shaw, Joseph, Desai, Sudha, Jayson, Gordon C., Woodward, Emma R., and Evans, D. Gareth R.

Subjects
GENETIC mutation, SEQUENCE analysis, SPECIALTY hospitals, DNA, BRCA genes, OVARIAN epithelial cancer, AGE distribution, GENETIC testing, MOLECULAR pathology, CANCER patients, CANCER treatment, STEM cells, DESCRIPTIVE statistics, RESEARCH funding, NUCLEIC acid amplification techniques
Abstract

Simple Summary: Approximately 10–15% of patients with epithelial ovarian cancer have an inherited (germline) BRCA1 or BRCA2 mutation. Following a diagnosis of epithelial ovarian cancer, patients are routinely tested for germline and/or somatic (tumour) BRCA1/2 mutations. Our study shows that if germline BRCA1/2 testing is only performed for patients with a positive tumour BRCA1/2 test result, and tumour testing is performed using Myriad's myChoice® companion diagnostic, a proportion of germline BRCA1/2 large rearrangements could be missed. If paired germline-tumour DNA testing is not possible for all patients, our data shows that it would be appropriate to test all patients with epithelial ovarian cancer aged < 79 years old for germline BRCA1/2 mutations, regardless of the tumour BRCA1/2 result, whilst only needing to test patients aged ≥ 80 years old for a germline BRCA1/2 mutation if they have a positive tumour BRCA1/2 result. Patients diagnosed with epithelial ovarian cancer may undergo reflex tumour BRCA1/2 testing followed by germline BRCA1/2 testing in patients with a positive tumour test result. This testing model relies on tumour BRCA1/2 tests being able to detect all types of pathogenic variant. We analysed germline and tumour BRCA1/2 test results from patients treated for epithelial ovarian cancer at our specialist oncological referral centre. Tumour BRCA1/2 testing was performed using the next-generation sequencing (NGS)-based myChoice® companion diagnostic (CDx; Myriad Genetics, Inc.). Germline BRCA1/2 testing was performed in the North West Genomic Laboratory Hub using NGS and multiplex ligation-dependent probe amplification. Between 11 April 2021 and 11 October 2023, 382 patients were successfully tested for tumour BRCA1 and BRCA2 variants. Of these, 367 (96.1%) patients were tested for germline BRCA1/2 variants. In those patients who underwent tumour and germline testing, 15.3% (56/367) had a BRCA1/2 pathogenic variant (36 germline and 20 somatic). All germline BRCA1/2 pathogenic small sequencing variants were detected in tumour DNA. By contrast, 3 out of 8 germline BRCA1/2 pathogenic large rearrangements were not reported in tumour DNA. The overall concordance of germline BRCA1/2 pathogenic variants detected in germline and tumour DNA was clinically acceptable at 91.7% (33/36). The myChoice® CDx was able to detect most germline BRCA1/2 pathogenic variants in tumour DNA, although a proportion of pathogenic large rearrangements were not reported. If Myriad's myChoice® CDx is used for tumour BRCA1/2 testing, our data supports a testing strategy of germline and tumour BRCA1/2 testing in all patients diagnosed with epithelial ovarian cancer aged < 79 years old, with germline BRCA1/2 testing only necessary for patients aged ≥ 80 years old with a tumour BRCA1/2 pathogenic variant. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

40. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial

Author

Oza, Amit M, Cook, Adrian D, Pfisterer, Jacobus, Embleton, Andrew, Ledermann, Jonathan A, Pujade-Lauraine, Eric, Kristensen, Gunnar, Carey, Mark S, Beale, Philip, Cervantes, Andrés, Park-Simon, Tjoung-Won, Rustin, Gordon, Joly, Florence, Mirza, Mansoor R, Plante, Marie, Quinn, Michael, Poveda, Andrés, Jayson, Gordon C, Stark, Dan, Swart, Ann Marie, Farrelly, Laura, Kaplan, Richard, Parmar, Mahesh K B, and Perren, Timothy J

Published
2015
Full Text
View/download PDF

41. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial

Author

Kehoe, Sean, Hook, Jane, Nankivell, Matthew, Jayson, Gordon C, Kitchener, Henry, Lopes, Tito, Luesley, David, Perren, Timothy, Bannoo, Selina, Mascarenhas, Monica, Dobbs, Stephen, Essapen, Sharadah, Twigg, Jeremy, Herod, Jonathan, McCluggage, Glenn, Parmar, Mahesh, and Swart, Ann-Marie

Published
2015
Full Text
View/download PDF

44. Data from Quantifying Antivascular Effects of Monoclonal Antibodies to Vascular Endothelial Growth Factor: Insights from Imaging

Author

O'Connor, James P.B., primary, Carano, Richard A.D., primary, Clamp, Andrew R., primary, Ross, Jed, primary, Ho, Calvin C.K., primary, Jackson, Alan, primary, Parker, Geoff J.M., primary, Rose, Chris J., primary, Peale, Franklin V., primary, Friesenhahn, Michel, primary, Mitchell, Claire L., primary, Watson, Yvonne, primary, Roberts, Caleb, primary, Hope, Lynn, primary, Cheung, Sue, primary, Reslan, Hani Bou, primary, Go, Mary Ann T., primary, Pacheco, Glenn J., primary, Wu, Xiumin, primary, Cao, Tim C., primary, Ross, Sarajane, primary, Buonaccorsi, Giovanni A., primary, Davies, Karen, primary, Hasan, Jurjees, primary, Thornton, Paula, primary, del Puerto, Olivia, primary, Ferrara, Napoleone, primary, van Bruggen, Nicholas, primary, and Jayson, Gordon C., primary

Published
2023
Full Text
View/download PDF

45. Supplementary Figures 4 - 8 from Predicting Response to Bevacizumab in Ovarian Cancer: A Panel of Potential Biomarkers Informing Treatment Selection

Author

Collinson, Fiona, primary, Hutchinson, Michelle, primary, Craven, Rachel A., primary, Cairns, David A., primary, Zougman, Alexandre, primary, Wind, Tobias C., primary, Gahir, Narinder, primary, Messenger, Michael P., primary, Jackson, Sharon, primary, Thompson, Douglas, primary, Adusei, Cybil, primary, Ledermann, Jonathan A., primary, Hall, Geoffrey, primary, Jayson, Gordon C., primary, Selby, Peter J., primary, and Banks, Rosamonde E., primary

Published
2023
Full Text
View/download PDF

46. Data Supplement from The Combination of Circulating Ang1 and Tie2 Levels Predicts Progression-Free Survival Advantage in Bevacizumab-Treated Patients with Ovarian Cancer

Author

Backen, Alison, primary, Renehan, Andrew G., primary, Clamp, Andrew R., primary, Berzuini, Carlo, primary, Zhou, Cong, primary, Oza, Amit, primary, Bannoo, Selina, primary, Scherer, Stefan J., primary, Banks, Rosamonde E., primary, Dive, Caroline, primary, and Jayson, Gordon C., primary

Published
2023
Full Text
View/download PDF

47. Supplementary Tables 1 - 8 from Predicting Response to Bevacizumab in Ovarian Cancer: A Panel of Potential Biomarkers Informing Treatment Selection

Author

Collinson, Fiona, primary, Hutchinson, Michelle, primary, Craven, Rachel A., primary, Cairns, David A., primary, Zougman, Alexandre, primary, Wind, Tobias C., primary, Gahir, Narinder, primary, Messenger, Michael P., primary, Jackson, Sharon, primary, Thompson, Douglas, primary, Adusei, Cybil, primary, Ledermann, Jonathan A., primary, Hall, Geoffrey, primary, Jayson, Gordon C., primary, Selby, Peter J., primary, and Banks, Rosamonde E., primary

Published
2023
Full Text
View/download PDF

48. Supplementary Figure Legend from Predicting Response to Bevacizumab in Ovarian Cancer: A Panel of Potential Biomarkers Informing Treatment Selection

Author

Collinson, Fiona, primary, Hutchinson, Michelle, primary, Craven, Rachel A., primary, Cairns, David A., primary, Zougman, Alexandre, primary, Wind, Tobias C., primary, Gahir, Narinder, primary, Messenger, Michael P., primary, Jackson, Sharon, primary, Thompson, Douglas, primary, Adusei, Cybil, primary, Ledermann, Jonathan A., primary, Hall, Geoffrey, primary, Jayson, Gordon C., primary, Selby, Peter J., primary, and Banks, Rosamonde E., primary

Published
2023
Full Text
View/download PDF

49. Supplementary Figures 1 - 3 from Predicting Response to Bevacizumab in Ovarian Cancer: A Panel of Potential Biomarkers Informing Treatment Selection

Author

Collinson, Fiona, primary, Hutchinson, Michelle, primary, Craven, Rachel A., primary, Cairns, David A., primary, Zougman, Alexandre, primary, Wind, Tobias C., primary, Gahir, Narinder, primary, Messenger, Michael P., primary, Jackson, Sharon, primary, Thompson, Douglas, primary, Adusei, Cybil, primary, Ledermann, Jonathan A., primary, Hall, Geoffrey, primary, Jayson, Gordon C., primary, Selby, Peter J., primary, and Banks, Rosamonde E., primary

Published
2023
Full Text
View/download PDF

50. Supplementary Methods from Predicting Response to Bevacizumab in Ovarian Cancer: A Panel of Potential Biomarkers Informing Treatment Selection

Author

Collinson, Fiona, primary, Hutchinson, Michelle, primary, Craven, Rachel A., primary, Cairns, David A., primary, Zougman, Alexandre, primary, Wind, Tobias C., primary, Gahir, Narinder, primary, Messenger, Michael P., primary, Jackson, Sharon, primary, Thompson, Douglas, primary, Adusei, Cybil, primary, Ledermann, Jonathan A., primary, Hall, Geoffrey, primary, Jayson, Gordon C., primary, Selby, Peter J., primary, and Banks, Rosamonde E., primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results